Key Takeaways
- • The Terry Fox Foundation and Lumira Ventures have launched The Cancer Breakthrough Fund, a first-of-its-kind collaboration in Canada pairing philanthropy with venture capital to accelerate cancer therapy commercialization.
- • The fund targets US$25 million in capital to invest in mission-driven cancer-focused companies, addressing a chronic funding gap in Canada's life sciences sector despite strong historical performance.
- • VC-backed healthcare companies have accounted for over 50% of novel products approved by the FDA over the past decade, yet Canada remains significantly under-capitalized relative to the U.S. in life sciences venture investment.
- • The Canadian Cancer Society is co-leading a historic $25 million investment in investigator-initiated cancer clinical trials, expanding the ecosystem's support for research translation into commercial products.
- • The partnership bridges government and philanthropic research funding with private sector expertise and investor networks, positioning Canadian cancer researchers to capture greater value domestically rather than ceding intellectual property gains to foreign investors.
Summary
The Terry Fox Foundation and Lumira Ventures have established The Cancer Breakthrough Fund, marking a strategic pivot toward venture capital-backed cancer research commercialization in Canada. Announced April 10, 2025, the fund represents the first major institutional collaboration between a philanthropic research organization and a venture firm focused explicitly on building scalable cancer therapy companies. The fund targets US$25 million in capital and will be managed by Lumira Ventures, leveraging the Terry Fox Foundation's network of leading cancer researchers alongside Lumira's investor relationships and track record in building and scaling life sciences companies.
The initiative addresses a well-documented structural gap in Canadian healthcare innovation financing. Peter van der Velden, Managing General Partner at Lumira Ventures, noted that despite the life sciences sector outperforming all other innovation sectors over the past decade in both Canada and the U.S., and despite VC-backed healthcare companies accounting for over 50% of novel FDA-approved products delivered to patients, Canada remains chronically under-capitalized. This funding disparity has historically allowed foreign investors to capture the majority of value generated from Canadian-based life science innovations.
Concurrent with the Lumira partnership, the Canadian Cancer Society has co-led a separate historic $25 million investment in investigator-initiated cancer clinical trials, working alongside the Terry Fox Research Institute. This dual-track approach signals institutional recognition that accelerating research toward commercialization requires bridging the traditional divide between government-funded and philanthropically-supported research on one side, and private-sector capital, expertise, and commercialization networks on the other. The Terry Fox Foundation has previously raised over $1 billion for cancer research, establishing credibility as a capital steward, while the new partnership structures that capital toward company-building and product development rather than research funding alone.
The initiative addresses a well-documented structural gap in Canadian healthcare innovation financing. Peter van der Velden, Managing General Partner at Lumira Ventures, noted that despite the life sciences sector outperforming all other innovation sectors over the past decade in both Canada and the U.S., and despite VC-backed healthcare companies accounting for over 50% of novel FDA-approved products delivered to patients, Canada remains chronically under-capitalized. This funding disparity has historically allowed foreign investors to capture the majority of value generated from Canadian-based life science innovations.
Concurrent with the Lumira partnership, the Canadian Cancer Society has co-led a separate historic $25 million investment in investigator-initiated cancer clinical trials, working alongside the Terry Fox Research Institute. This dual-track approach signals institutional recognition that accelerating research toward commercialization requires bridging the traditional divide between government-funded and philanthropically-supported research on one side, and private-sector capital, expertise, and commercialization networks on the other. The Terry Fox Foundation has previously raised over $1 billion for cancer research, establishing credibility as a capital steward, while the new partnership structures that capital toward company-building and product development rather than research funding alone.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.